Pregnenolone

What pregnenolone is and how it works

Pregnenolone is the steroid the body makes first. Cholesterol is converted to it inside the mitochondria of steroid-producing tissue, and everything downstream — progesterone, DHEA, cortisol, testosterone, the estrogens — is made from it or from something made from it. That position is the entire lay argument for taking it, usually stated as some version of "it is the mother hormone, so it will top up everything below it."

Position in a pathway is a mechanism, not an outcome, and the one study that looked directly does not support the argument. Five male volunteers were given a single 50 mg oral dose in an open excretion study designed to find urinary markers of administration. Ingestion produced no significant effect on the testosterone-to-epitestosterone or the testosterone-to-luteinising-hormone ratio; what did change, variably, were the carbon isotope signatures of androsterone, etiocholanolone and other testosterone metabolites, remaining distinguishable for over 40 hours.^[11] In other words, an oral dose demonstrably enters steroid metabolism and demonstrably does not move the testosterone ratios the precursor argument predicts, in five men. That is a small study and it is the direct evidence that exists.

The other mechanism attached to this compound is neurological rather than endocrine, and it runs through metabolites rather than through pregnenolone itself. Pregnenolone is converted to allopregnanolone, a positive modulator of GABA-A receptor responses, and to pregnenolone sulfate, which acts on NMDA receptor signalling; reviews describe pregnenolone, 7α-hydroxypregnenolone, pregnenolone sulfate and allopregnanolone as distinct entities binding distinct cytoplasmic and membrane targets.^[12] That distinction matters more than it sounds. Pregnenolone sulfate is a different, much more studied entity than pregnenolone; allopregnanolone is a different entity again; and several allopregnanolone-related neuroactive steroids have been developed into approved prescription drugs for postpartum depression and for seizures. Pregnenolone is not one of them, and none of their evidence is its evidence. The one thing the human trials do consistently show is that taking pregnenolone raises allopregnanolone.^[9]

DHEA sits one step downstream on the adrenal branch of the same pathway and has its own reference page here. It is a different molecule with a different and much larger randomized literature, and one of the trials below deliberately ran DHEA as a separate arm against pregnenolone rather than treating the two as interchangeable.^[2]

What the research actually shows

The shape of the literature is the first thing to know, because it is not the shape the shelf implies. A PubMed search for pregnenolone on 1 September 2026 returned 8,123 records; pregnenolone AND randomized controlled trial[pt] returned 40, of which 39 also carry the humans index term, and pregnenolone AND schizophrenia AND randomized controlled trial[pt] returned 7. A search for pregnenolone AND anti-aging on the same database on the same day returned 1 record in total, and pregnenolone AND longevity returned 5. The randomized human evidence for this compound is concentrated almost entirely in adjunctive psychiatric treatment. Sources here were selected by taking the trials PubMed indexes as randomized controlled trials that administered pregnenolone to humans, reporting for each what its pre-specified primary endpoint did before any secondary result, treating same-cohort reports as one study, and adding the mechanism and pharmacology work needed to state the boundaries.

The largest trial is the most important and its cognitive endpoint failed. One hundred and twenty participants were randomized to pregnenolone or placebo for eight weeks after a placebo lead-in, with three pre-specified primary endpoints: a cognitive battery composite, a functional-capacity composite, and a negative-symptom total. No significant change against placebo was demonstrated on the cognitive composite. Functional capacity did improve (p = 0.03, 56 against 55 participants), and the communication subscale within it improved more strongly. Negative-symptom scores were very low at baseline and did not improve further.^[1] One of three primary endpoints was met.

The earlier pilot from the same programme is small and points the same way. Twenty-one patients were randomized and 18 completed at least four weeks, nine per group, on fixed escalating amounts to 500 mg daily. Negative-symptom scores improved significantly (mean change 10.38 against 2.33, p = 0.048), while mean composite changes on both cognitive batteries were not significantly different from placebo.^[3]

Two trials from a second group report the same 60-patient cohort. An 8-week add-on trial in 60 out- and inpatients with recent-onset illness reported significantly reduced negative symptoms with moderate effect sizes, d = 0.79 on one scale and d = 0.57 on another, with benefit at weeks six and eight confined to patients not also taking mood stabilisers, and no significant effect on other symptoms, functioning or side effects.^[4] The companion paper reports the cognitive outcomes of that same 60-patient trial: a significant between-group improvement on one computerised visual-attention task, p = 0.002 with d = 0.42, with the executive and sustained-attention gains described as baseline-to-endpoint changes within the treated group.^[5] Those are one trial reported twice, not two replications.

The dose result inside a single trial is the sharpest caveat available. A four-arm 8-week trial in 58 patients compared 30 mg daily, 200 mg daily, a DHEA arm and placebo. The 30 mg arm showed significant reductions in positive symptoms and extrapyramidal side effects and improved attention and working memory. The 200 mg arm did not differ from placebo on any outcome variable, and negative symptoms were not significantly benefited by any treatment.^[2] More was not better, and a substance whose lower arm outperforms its higher arm inside one trial is not one whose amounts can be treated as a scale.

The cleanest negative is a trial of 82 women. Randomized to risperidone plus either 50 mg daily pregnenolone or placebo for eight weeks, its primary endpoint — total symptom-scale change at week eight — was not met (mean difference −9.41, 95% CI −20.24 to 1.41, p = 0.087). The negative-subscale and general-psychopathology differences that were nominally significant did not survive Bonferroni correction for multiple testing, and the authors say so.^[6] Outside schizophrenia the picture is the same: in 70 participants with a mood disorder and a substance-use history, titration to 100 mg daily produced trends only, with significance appearing solely in a post hoc completer analysis and no cognitive benefit at all;^[8] and in an obsessive-compulsive disorder pilot published as an interim letter, exposure therapy worked while no effects of pregnenolone against placebo pretreatment were detectable.^[10] A combination trial of 50 mg daily pregnenolone given with 400 mg daily L-theanine in 40 patients did meet both of its co-primary endpoints — but both substances were in the same arm, so it cannot say which one did it.^[7]

Where the evidence is weak

The compound-level grade on this page is anecdotal, and the reason is worth stating plainly. There are a dozen randomized trials of this molecule and several of them are decent. Every one of them administered it to people with a psychiatric diagnosis, almost always on top of antipsychotic medication. The claim readers actually arrive with — memory, mental sharpness, hormonal rejuvenation in an otherwise healthy adult — has no randomized evidence at all: a PubMed search for pregnenolone AND healthy AND memory AND randomized controlled trial[pt] on 1 September 2026 returned 0 records, and pregnenolone AND aging AND randomized controlled trial[pt] returned 0 on the same day. The grade describes that claim, not the adjunctive psychiatric literature, because a badge earned in one population and displayed above prose about another is exactly the mistake this page exists to avoid.^[1]

The randomized set is a small literature from a small number of groups. Matching on the surname-plus-initials string exactly as PubMed prints it in each record's author list, one senior author appears on four of the twelve records cited here — including the two that report the same 60-patient cohort — and a second appears on three. Seven of twelve carry one of two recurring senior authors. That is not a criticism of any paper; it is a statement about how much independent replication this evidence base actually contains, and the answer is less than a count of trials suggests.^[2][1]

The endpoints are symptom scales and brain images, not the things people take this for. No trial on this page measured memory in a person who did not have a psychiatric diagnosis, measured any outcome over more than eight weeks, or measured a hormonal endpoint as a primary outcome. The imaging study measured regional brain activity after a single dose — a pharmacological effect, not a clinical one.^[9] The one study that measured what the precursor argument predicts found the testosterone ratios unchanged.^[11]

"Well tolerated" is doing more work than it can bear. The tolerability statements in this literature come from eight weeks of exposure in between 21 and 120 participants.^[1][3][2] Studies that size and that short are built to detect symptom change; they cannot detect uncommon or long-latency harm, and nothing published describes a year of use.

And the supplement shelf is not evidence of anything. Being available over the counter is a fact about how a substance is distributed. It is not a finding that it works, not a finding that it is safe, and not a substitute for the trials above — which is why the regulatory position below is stated as regulatory position and nothing more.

Legal and regulatory status

There is no FDA-approved drug product containing pregnenolone. Queried on 1 September 2026, openFDA drug/drugsfda returned no matches on products.active_ingredients.name, on openfda.generic_name or on openfda.substance_name, each returning HTTP 404 NOT_FOUND. In the same session on the same database, products.active_ingredients.name for TESTOSTERONE returned 88 applications, so the query shape works and the zero is a real zero.

The drug/label endpoint on openfda.substance_name returned 6 records on the same day, and reading all six, every one is a human over-the-counter product categorised as an unapproved homeopathic combination containing between three and nine declared substances, and not one of them is a pregnenolone-only product. A national drug code directory query on generic_name returned 14 records: reading marketing_category and product_type on every row, five are registered as bulk ingredient, four as bulk ingredient for human prescription compounding, four are those same unapproved homeopathic over-the-counter combinations, and one is registered as a drug for further processing. An ingredient registration is not an approval and a homeopathic listing is not an approval.

FDA's own two compounding documents place it in different categories and both are worth stating exactly. Pregnenolone appears in FDA's 503A bulk drug substance nomination category lists, in the document self-dated Updated May 14, 2026, under Category 1 — Bulk Drug Substances Under Evaluation. In the separate 503B outsourcing facility bulks list, self-dated Updated March 21, 2025, "Pregnenolone micronized" appears under Category 3: Bulk Drug Substances Nominated Without Adequate Support — FDA's own designation for substances nominated with too little information for the agency to evaluate them. Neither placement is an approval, a compounding authorisation or a finding of safety or efficacy, and the Category 3 entry is the opposite of a clearance. The substance appears on neither table of FDA's separate page on bulk drug substances for use in compounding that may present significant safety risks, whose content is stamped current as of 22 April 2026 and which does name a number of other research compounds; that null was run alongside in-document positive controls that did return entries.

What this page does not claim. Pregnenolone is sold over the counter in the United States. Whether it lawfully holds dietary-supplement status under the Dietary Supplement Health and Education Act is a question no primary source located in this session answered — no old-dietary-ingredient determination and no new-dietary-ingredient notification was found — so this page states the shelf as an observation and asserts nothing about its statutory basis. The verifiable picture is the one above: no approved drug product on any of three openFDA fields, Category 1 on one FDA compounding list and Category 3 on the other, and the only finished products in FDA's own label database are unapproved homeopathic combinations.

FDA's orphan drug designation database returned "No records found" for pregnenolone on 1 September 2026, against a same-session product-name search for testosterone that returned 9 designations; that answer came from submitting the database's own search form in a browser, because a scripted request to the results endpoint returned the empty form even for the control, and an HTTP behaviour is a fact about a route rather than about a register. A full-text search of FDA's warning-letter index on the same day returned no letters naming pregnenolone, against a same-session sildenafil control that did return results. openFDA drug/enforcement returned 2 records, both Class II recalls of compounded preparations — a 20 mg sustained-release capsule in 2015 and a 100 mg prescription-only pellet in 2018 — each recalled for lack of assurance of sterility, in one case alongside stability data that did not support the assigned expiry. Those are compounding-quality events and are not enforcement findings about the substance itself.

Anti-doping. The 2026 World Anti-Doping Code International Standard Prohibited List, in force from 1 January 2026, was retrieved on 1 September 2026 from the WADA-hosted document linked by the United States Anti-Doping Agency's prohibited-list page. Pregnenolone is not named on it under any of the spellings searched — "pregnenolone", "pregnen" and "pregnanolone" each return nothing anywhere in the document — and it is not on the 2026 Monitoring Program, retrieved the same day, whose entries are ecdysterone, gonadotrophin-releasing hormone analogues in females under 18, hypoxen, seven stimulants, seven narcotics and markers of two incretin drugs. Absence from the List is never a statement that a substance is permitted, and here that clause is doing real work. Section S1.1 of the same List names the adjacent adrenal precursor "Prasterone (dehydroepiandrosterone, DHEA, 3ß-hydroxyandrost-5-en-17-one)" among the anabolic androgenic steroids, which are prohibited at all times and are all non-Specified Substances; pregnenolone sits one step upstream of that branch of the same pathway. The practical hazard for anyone in a tested sport is therefore a finding about a downstream substance rather than about this one, and the excretion study above shows that an oral dose leaves a detectable metabolic signature for more than 40 hours.^[11]

The provision that could reach an unnamed substance is S0, and this page cannot resolve it. Section S0, headed "S0 NON-APPROVED SUBSTANCES" in the same retrieved document, is "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)" and states that "All prohibited substances in this class are Specified Substances." Its trigger reads: "Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times." Those are two conditions joined by "and", so both must hold. The first is satisfied here: the dated full-text searches described above find pregnenolone nowhere in the document, so it is not addressed by any subsequent named section of the List. The second turns on approval by any governmental regulatory health authority for human therapeutic use — not only the United States one this page examined — and no non-US regulator was checked in the session behind this page. So whether S0 reaches pregnenolone is undetermined here. That is a statement about what was verified, not a finding: it is not a conclusion that S0 does not apply, and it is not a conclusion that it does. Anyone competing under an anti-doping code resolves that question with their own anti-doping organization rather than from this page.

The List is reissued annually and anyone competing reads the year in force at first hand rather than this page.

Peptide Health Lab does not sell anything, does not prescribe, and does not tell anyone where to obtain anything. The regulatory picture appears here only because it changes what the evidence above can and cannot support.

Questions to bring to a provider

The useful questions all come back to which population the evidence is about and what would count as it working:

• What is the specific target — memory, mood, anxiety, a hormone level — and how would anyone tell whether it changed, given that the trials measured psychiatric symptom scales in patients already on medication?^[1]
• If the goal is raising downstream hormones, what would be measured before and after, given that the one study that looked found the testosterone ratios unchanged after an oral dose?^[11]
• Does an eight-week evidence base support an open-ended plan, and what would trigger stopping?^[4]
• How does this interact with anything already being taken that acts on GABA receptors — sedatives, alcohol, psychiatric medication — given that the measurable central effects run through allopregnanolone?^[9][12]
• Does any personal or family history of a hormone-sensitive condition change the discussion for a substance that sits upstream of the sex hormones and cortisol?^[12]
• Since there is no approved product, what is actually known about the identity and strength of whatever is being considered, and who is checking?
• If the interest came from reading about neurosteroid drugs, is the substance in question actually this one, or one of the distinct related molecules with their own approvals and their own trials?^[12]

A clinician who answers "the trials for that use have not been done" is reporting the literature accurately.